Safe handling of cytotoxic compounds in a biopharmaceutical environment

Methods in Molecular Biology

Volumn 1045, Issue , 2013, Pages 133-143

  Hensgen, Miriam I ^a   Stump, Bernhard ^a  

^a LONZA AG   (Switzerland)

Author keywords

Antibody drug conjugates; Cytotoxic compounds; Handling; Occupational exposure

Indexed keywords

CYTOTOXIC AGENT;

ARTICLE; DANGEROUS GOODS; DRUG INDUSTRY; HUMAN; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; RISK ASSESSMENT; SAFETY; SPILLAGE; WASTE MANAGEMENT; WORK ENVIRONMENT;

EID: 84934434464     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-541-5_8     Document Type: Article

References (18)

1. Harris CC (1976) The carcinogenicity of anticancer drugs: A hazard in man. Cancer 37:1014-1023
2. Hughes B (2010) Antibody-drug conjugates for cancer: Poised to deliver? Nat Rev Drug Discov 9:665-667
3. AxonMW, Farris JP, Mason J (2008) Handling highly potent active pharmaceutical ingredients. Chem Today 26:57-61
4. Thayer AM (2008) Contained chemistry. Synthesizing highly potent compounds is a lucrative and growing niche for custom chemical manufacturers. Chem Eng News 86:17-27
5. Rohrer T (2010) Challenges in the manufacturing of antibody drug conjugates. Innovat Pharmaceut Tech 10-12 http://www. iptonline.com/articles/ public/p10-12%20nonprint. pdf
6. The State ofQueensland (Department of Industrial Relations) (2005) Queensland workplace health and safety strategy: Guide for handling cytotoxic drugs and related waste. See http:// www.deir.qld.gov.au/workplace/resources/ pdfs/cytotoxicdrugs-guide2006.pdf
7. Canadian Association of University Teachers (2011) Cytotoxic drugs fact sheet. 25:1-4 http://cupe.ca/health-Andsafety/cytotoxicdrugs
8. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Bla WA, Chari RVJ (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49:4392-4408
9. Alley SC, Zhang X, Okeley NM, Anderson M, Law C-L, Senter PT, Benjamin DR (2009) The pharmacologic basis for antibody-Auristatin conjugate activity. J Pharmacol Exp Ther 330:932-938
10. Yu T-W, Bai L, Clade D, Hoffmann D, Toelzer S, Trinh KQ, Xu J, Moss SJ et al (2002) The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum. Proc Natl Acad Sci USA 99:7968-7973
11. Younes A, Yasothan U, Kirkpatrick P (2012) Brentuximab vedotin. Nat Rev Drug Discov 11:19-20
12. Colls BM (1985) Safety of handling cytotoxic agents: A cause for concern by pharmaceutical companies? Br Med J 291:1318-1319
13. Connor TH,McDiarmidMA(2006) Preventing occupational exposures to antineoplastic drugs in health care settings. Cancer J Clin 56:354-365
14. Bormett D (2009) Antibody drug conjugate: A new set of handling and quality control measures. Chem Today 27:23-25
15. Farris JP, Ader AW, Ku RH (2006) History, implementation and evolution of the pharmaceutical hazard categorization and control system. Chem Today 24:5-10
16. Ader AW, Kimmel TA, Sussman RG (2009) Applying health-based risk assessments to worker and product safety for potent pharmaceuticals in contract manufacturing operations. Pharm Outsourcing 10:48-53
17. Watkins KJ (2001) Handle with care -contract pharmaceutical manufacturers find a niche in handling high-potency active ingredients. Chem Eng News 79:31-34
18. Allwood M, Stanley A, Wright P (2002) The cytotoxics handbook, 4th edn. Radcliffe Medical Press, Oxford 19. A1 SafeTech containment strategies, Expositionsschutz durch offene Containments, see http://www.a1-safetech.ch/ assets/files/a1safetech- containment-technologies-2012.pdf